Wisp is making a play to become a much broader women’s healthcare platform, expanding beyond the sexual and reproductive health services on which it built its business into fertility, diagnostics, menopause and longer-term health and wellness.
The US telehealth company says it has now served two million patients nationwide and has appointed DTC executive Keira Krausz as CEO to lead its next phase of growth.
“Two million patients is proof that women are looking for a fundamentally different healthcare experience – one that takes them seriously, fits into their lives, and doesn’t make them jump through hoops to get the care they need,” said Keira.
“Wisp has already changed the way millions of women access sexual and reproductive care. Now, we have an opportunity to bring that same experience to more of women’s health and build a platform that can be there for them not just for one moment, but for decades.”
Turning national scale into broader impact
Founded in 2018, Wisp built its initial proposition around making sexual and reproductive healthcare easier to access online, spanning areas including birth control, STI and UTI care. Eight years on, it now operates across all 50 US states and is looking to use that scale and existing patient relationship to serve women across more stages of their lives.
Its expanding portfolio includes fertility and menopause care, at-home diagnostics and testing, prescription skincare, vaginal probiotics and supplements. In January 2026, Wisp also acquired sexual health provider TBD Health, adding its clinical infrastructure and diagnostics capabilities to the platform.
The ambition is to move from providing care around individual episodes to becoming what Wisp describes as a “continuous health-span companion” - a healthcare platform women can return to as their needs change throughout their lives.
Keira Krausz joins as Wisp attempts to translate its position in direct-to-consumer reproductive healthcare into a longer-term relationship with patients. The company’s strategy is based on the idea that needs currently treated as separate healthcare episodes - from contraception and infections to fertility, diagnostics, perimenopause and menopause - could instead be served through the same consumer platform.
That also puts Wisp within a broader shift across women’s digital health, as companies that initially built scale around a particular high-frequency or underserved need increasingly expand across conditions and life stages.
The Wisp proposition combines 24/7 telehealth with at-home testing and personalised treatment plans, with the aim of giving patients a more consistent route into care regardless of where they live.
Wisp is majority-owned by Canadian digital health company WELL Health Technologies.